EUVIMEDEUVIMED entdecken
Crossref

Integrated Serum Pharmacochemistry, Metabolomics, and Network Pharmacology Uncover Potential Active Components and Mechanisms of Shenling Baizhu Powder in Treating Ulcerative Colitis With Spleen Deficiency and Dampness Stagnation

Bixin Shen, Zhenyu Yang, Yixiao Pan, Weijin Yang, Jing Chen

Biomedical Chromatography · 2026-06 · 40 (6)

DOI: 10.1002/bmc.70476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 06.05.2026. Verfasst von Bixin Shen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Colitis, Ulcerative, Splenic Diseases. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Zhejiang Provincial Natural Science Foundation of China, National Natural Science Foundation of China, Program for High Level Talents in Taizhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study combined serum pharmacochemistry, metabolomics, and network pharmacology to uncover potential active components and mechanisms of Shenling Baizhu Powder (SLBZP) in treating ulcerative colitis with spleen deficiency and dampness stagnation (UC‐SDDS), providing scientific evidence for its efficacy. Pharmacodynamic investigations demonstrated that SLBZP exhibits substantial anti‐inflammatory properties and confers protection to the intestinal barrier in UC‐SDDS rat models. Further, 16 active components and six core targets (BCL2, NFKB1, TNF, IL6, AKT1, CASP3) were obtained using serum pharmacochemistry and network pharmacology. Twenty‐six differential metabolites in serum and 25 differential metabolites in urine were identified using untargeted metabolomics analyses. Subsequently, nine active components (butein, calycosin‐7‐o‐β‐d‐glucoside, glabridin, isochlorogenic acid B, naringenin chalcone, naringenin, neoliquiritin, oroxyloside, and vanillic acid) were identified from SLBZP for treating UC‐SDDS by integrating network pharmacology and chinmedomics. Molecular docking and dynamics simulation revealed that these compounds exhibit superior binding affinities to six core targets. Finally, the expression levels of AKT1, p‐AKT1, mTOR, Caspase 3, TLR2, TLR4, ERK1/2, STAT1, MyD88, NFκB, and BCL2 in colon tissues were detected in UC‐SDDS rats treated with SLBZP. The study showed that SLBZP effectively treats UC‐SDDS rats by modulating multiple components, targets, and pathways using serum pharmacochemistry, network pharmacology, and metabolomics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, Chinese HerbalColitis, UlcerativeSplenic DiseasesAnimalsMetabolomicsRatsMaleNetwork PharmacologyRats, Sprague-DawleyMetabolomeSpleenAnti-Inflammatory Agents

Stichwörter der Autor:innen

Shenling Baizhu powderdampness stagnancymetabolomicsserum pharmacochemistryspleen deficiencyulcerative colitis

Substanzen

Drugs, Chinese HerbalAnti-Inflammatory AgentsBaizhu

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China.
  • Department of Pharmacy, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Lin Hai, Zhejiang, China.
  • Taizhou Key Laboratory of Pharmaceuticals Therapy and Translation Research, Lin Hai, Zhejiang, China.

Förderung

  • Zhejiang Provincial Natural Science Foundation of China
  • National Natural Science Foundation of China
  • Program for High Level Talents in Taizhou
  • Zhejiang province health high-level innovative talents
  • Zhejiang Province TCM Science and Technology plan
  • Scientific researching fund of Taizhou Enze Medical Center (Group)
  • Doctoral Start-up Fund of Taizhou Enze Medical Center (Group)

Zitieren

APA

Shen, B., Yang, Z., Pan, Y., Yang, W., & Chen, J. (2026). Integrated Serum Pharmacochemistry, Metabolomics, and Network Pharmacology Uncover Potential Active Components and Mechanisms of Shenling Baizhu Powder in Treating Ulcerative Colitis With Spleen Deficiency and Dampness Stagnation. Biomedical Chromatography, 40(6). https://doi.org/10.1002/bmc.70476

Vancouver

Shen B, Yang Z, Pan Y, Yang W, Chen J. Integrated Serum Pharmacochemistry, Metabolomics, and Network Pharmacology Uncover Potential Active Components and Mechanisms of Shenling Baizhu Powder in Treating Ulcerative Colitis With Spleen Deficiency and Dampness Stagnation. Biomedical Chromatography. 2026;40(6). doi:10.1002/bmc.70476

BibTeX
@article{Shen2026,
  author = {Shen, Bixin and Yang, Zhenyu and Pan, Yixiao and Yang, Weijin and Chen, Jing},
  title = {Integrated Serum Pharmacochemistry, Metabolomics, and Network Pharmacology Uncover Potential Active Components and Mechanisms of Shenling Baizhu Powder in Treating Ulcerative Colitis With Spleen Deficiency and Dampness Stagnation},
  journal = {Biomedical Chromatography},
  year = {2026},
  volume = {40},
  number = {6},
  doi = {10.1002/bmc.70476}
}
Kostenlos starten →